Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- OA-Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction
Forlagets udgivne version, 854 KB, PDF-dokument
Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.
Methods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class >= II, ejection fraction
Conclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.
Originalsprog | Engelsk |
---|---|
Tidsskrift | European Journal of Heart Failure |
Vol/bind | 22 |
Udgave nummer | 11 |
Sider (fra-til) | 2160-2171 |
ISSN | 1388-9842 |
DOI | |
Status | Udgivet - 2020 |
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
ID: 251577468